1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 20,300 | 22,500 | 23:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:59 | Milan: Gains for Philogen | - | Teleborsa | ||
| Mi | Milan: Philogen trades in negative territory | 1 | Teleborsa | ||
| PHILOGEN Aktie jetzt für 0€ handeln | |||||
| 13.01. | Milan: Downside move for Philogen | 1 | Teleborsa | ||
| 01.12.25 | Philogen stock rating downgraded to Neutral by Goldman Sachs | 7 | Investing.com | ||
| 01.12.25 | Goldman Sachs stuft Philogen auf 'Neutral' herab | 3 | Investing.com Deutsch | ||
| 11.06.25 | Philogen S.p.A.: Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.3 | 1.099 | GlobeNewswire (Europe) | Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales
OTELFINGEN... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 309,11 | -1,65 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| COGENT BIOSCIENCES | 37,960 | +5,62 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,74 | +0,22 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,650 | -0,27 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,500 | +1,16 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,060 | -2,77 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ARCELLX | 69,47 | +1,67 % | Arcellx präsentiert Daten zu Anito-Cel auf den Tandem Meetings 2026 | ||
| ARCUTIS BIOTHERAPEUTICS | 25,570 | +0,79 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis | 58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 75,62 | +3,97 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 65,93 | +2,06 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| QIAGEN | 44,060 | -0,62 % | Qiagen: Das ist gewagt! | Dass die sonst zu den ruhigen DAX-Aktien gehörende Qiagen auf einmal in kurzer Zeit einen Kurssprung von in der Spitze 21 Prozent hinlegt, zieht Aufmerksamkeit auf sich. Aber könnte man der Aktie neben... ► Artikel lesen | |
| BIONTECH | 92,40 | -3,75 % | BASF unter DRUCK! KAUFEMPFEHLUNGEN für BioNTech und WashTec Aktie! | Marktführerschaft, Effizienzsteigerung, Dividende und Aktienrückkauf - alles gute Gründe, um die Aktie von WashTec zu kaufen. Diese Einschätzung teilen auch die Analysten von MM Warburg. Ihre Gewinnschätzungen... ► Artikel lesen | |
| ERASCA | 10,610 | +0,81 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| RECURSION PHARMACEUTICALS | 4,175 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| LENZ THERAPEUTICS | 16,300 | +3,10 % | New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug |
PHILOGEN SPA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,300 (+1,42 %) liegt der Kurs bei 21,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHILOGEN SPA finden Sie auf Wallstreet Online.